Selective inhibition of sheep kidney 11β-hydroxysteroid dehydrogenase isoform 2 activity by 5α-reduced (but not 5β) derivatives of adrenocorticosteroids

Steroids

Volumn 62, Issue 2, 1997, Pages 230-237

  Latif, Syed A ^a   Sheff, Michael F ^a   Ribeiro, Carla E ^a   Morris, David J ^a  

^a MIRIAM HOSPITAL   (United States)

Author keywords

11 hydroxysteroid dehydrogenase isoform 2; 11 hydroxysteroid dehydrogenase isoform I; 5 metabolites; adrenocorticosteroids; inhibitors; progesterone metabolites

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; CORTICOSTEROID; ISOENZYME; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; PROGESTERONE;

ARTICLE; CONFORMATIONAL TRANSITION; CORTICOSTEROID METABOLISM; ENZYME ACTIVITY; ENZYME CONFORMATION; ENZYME INHIBITION; ESSENTIAL HYPERTENSION; NONHUMAN; PATHOGENESIS; SHEEP;

11-BETA-HYDROXYSTEROID DEHYDROGENASES; ADRENAL CORTEX HORMONES; ANIMALS; ENZYME INHIBITORS; HYDROXYSTEROID DEHYDROGENASES; ISOENZYMES; KIDNEY; MICROSOMES; PROGESTERONE; RATS; SHEEP;

EID: 0031081798     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-128X(96)00208-5     Document Type: Article

References (34)

1. 1. Edwards CRW, Burt D, McIntyre MA, DeKloet ER, Stewart PM, Brett L, Sutanto WS, Monder C. (1988). Localization of 11β-hydroyxsteroid dehydrogenase: Tissue-specific protector of the mineralocorticoid receptor. Lancet 2:986-989.
2. 2. Funder JW, Pearce PT, Smith R, Smith AI (1988). Mineralocorticoid action: Target tissue specificity is enzyme not receptor mediated. Science 242:583-585.
3. 3. Ulick S, Ramires LC. New MI (1977). An abnormality in steroid reductive metabolism in a hypertensive syndrome. J Clin Endocrinol Metab 44:799-802.
4. 4. Ulick S, Levine LS, Gunczler P, Zanconato G, Ramirez LC, Rauh W, Rosler A, Bradlow HL, New M (1979). A syndrome of apparent mineralocorticoid excess associated with defects in the peripheral metabolism of cortisol. J Clin Endocrin Metab 49:757-764.
5. 5. Wilson RC, Harbison MD, Krozowski ZS, et al. (1995). Several homozygous mutations in the gene for 11β-hydroxysteroid dehydrogenase type 2 in patients with apparent mineralocorticoid excess. J Clin Endocrin Metab 80:3145-3150.
6. 6. Mune T, Rogerson FM, Nikkila H, Agarwal AK, White PC (1995). Human hypertension caused by mutations in the kidney isozyme of 11beta-hydroxysteroid dehydrogenase. Nature Genetics 10:394-399.
7. 7. Rusvai E, Naray-Fejes-Toth, A (1993). A new isoform of 11β-hydroxysteroid dehydrogenase in aldosterone target cells. J Biol Chem 268:10717-10720.
8. 8. Naray-Fejes-Toth A, Watlington CO, Fejes-Toth G (1991). 11β-Hydroxysteroid dehydrogenase activity in the renal target cells of aldosterone. Endocrinology 129:17-21.
9. 9. Kenouch S, Alfaidy N, Bonvalet JP, Farman N (1994). Expression of 11β-OHSD along the nephron of mammals and humans. Steroids 59:100-104.
10. 10. Souness GW, Morris DJ (1989). The antinatriuretic and kaliuretic effects of corticosterone and cortisol following pretreatment with carbenoxolone sodium (a licorice derivative) in the adrenalectomized rat. Endocrinology 124:1588-1590.
11. 11. Souness GW, Morris DJ (1993). The "mineralocorticoid-like" actions conferred on corticosterone by carbenoxolone are inhibited by the mineralocorticoid receptor (type I) antagonist RU28318. Endocrinol 129:2451-2456.
12. 12. Monder C, White PC (1993). 11β-Hydroxysteroid dehydrogenase. Vitamins and Hormones 47:187-269.
13. +-dependent 11β-hydroxysteroid dehydrogenase in sheep kidney and JEG-3 cells, Proceedings of the Endocrine Society 77th Annual Meeting, Washington DC, Abstract P2-490, p. 413.
14. +retention. Steroids 59:352-356.
15. 15. Murphy BEP (1981). Demonstration of novel compounds in human fetal tissues and a consideration of their possible role in parturition. Am J Obstet Gynecol 139:353-358.
16. 16. Naray-Fejes-Toth A, Fejes-Toth G (1995). Expression cloning of the aldosterone target cell-specific 11 beta-hydroxysteroid dehydrogenase from rabbit collecting duct cells. Endocrinology 136:2579-2586.
17. 17. Lopez-Bernal A, Flint APF, Anderson ABM, Turnbull AC (1979). 11β-hydroxysteroid dehydrogenase activity (E.C.1.1.1.146) in human placenta and decidua. J Steroid Biochem 13:1081-1087.
18. 18. Stewart PM (1994). Properties of 11β-hydroxysteroid dehydrogenase, isoform 2. Program of the 25th International Aldosterone Symposium, Anaheim CA, June 1994.
19. 19. Souness GW, Latif SA, Laurenzo JL, Morris DJ (1995). 11α- and 11β-hydroxyprogesterone, potent inhibitors of 11β-hydroxysteroid dehydrogenase (isoforms 1 and 2), confer marked mineralocorticoid activity on corticosterone in the ADX rat. Endocrinology 136:1809-1812.
20. +-dependent isoform of 11 beta-hydroxysteroid dehydrogenase. Cloning and characterization of cDNA from sheep kidney. J Biol Chem 269:25959-25962.
21. 21. Latif SA, Semafuko SEB, Morris DJ (1992). Effects of carbenoxolone administered acutely to adrenalectomized rats (in vivo) on renal and hepatic handling of corticosterone by 11β-hydroxysteroid dehydrogenase. Steroids 58:494-501.
22. 22. Perschel FH, Buhler H, Hierholzer K (1991). Bile acids and their amidates inhibit 11β-hydroxysteroid dehydrogenase obtained from rat kidney. Pflugers Arch 418:538-543.
23. 23. Monder C, Stewart PM, Lakshmi V, Valentino R, Burt D, Edwards CRW (1989). Liquorice inhibits corticosteroid 11β-dehydrogenase of rat kidney and liver: In vivo and in vitro studies. Endocrinology 125:1046-1053.
24. 24. Kornel L, Starnes WR, Holl SR Jr, Hill A (1969). Studies on steroid conjugates: VI. Quantitative paper chromatography of urinary corticosteroids in essential hypertension. J Clin Endocrinol Metab 29: 1608-1617.
25. 25. Soro A, Ingram MC, Tonolo G, Glorioso N, Fraser R (1995). Evidence of coexisting changes in 11β-hydroxysteroid dehydrogenase and 5β-reductase activity in subjects with untreated essential hypertension. Hypertension 25:67-70.
26. 26. Gorsline J, Latif SA, Morris DJ (1988). Changes in 5α- and 5β-reductase pathways of aldosterone metabolism by dietary sodium. Am J Hypertension 1:272-275.
27. 27. Latif SA, Conca TJ, Morris DJ (1990). The effects of the liquorice derivatives, glycyrrhetinic acid on hepatic 3α- and 3β-hydroxy dehydrogenases and 5α- and 5β-reductase pathways of metabolism of aldosterone in male rats. Steroids 55:52-58.
28. 28. Souness GW, Morris DJ (1996). Progesterone derivatives that inhibit 11β-hydroxysteroid dehydrogenase are also hypertensinogenic in the rat. Proceedings of the Endocrine Society 78th Annual Meeting, San Francisco, Abstract, pp. 1-740.
29. 29. Jacobs DR, Van Der Poll J, Gabrilove JL, Soffer LJ (1961). 17α-Hydroxy progesterone - A salt losing steroid relation to congenital adrenal hyperplasia. J Clin Endocr 21:909-922.
30. 30. New MI, Levine LS (1980). Hypertension of childhood with suppressed renin. Endocrin Reviews 1:421-429.
31. 31. Chapman TE, Kraan GP, Nagel GT, Wolthers BG, Drayer NM (1991). Measurement of the cortisol production rate in two sisters with 17α-dydroxylase deficiency using [1,2,3,4-13C] cortisol and isotope dilution mass spectrometry. J Steroid Biochem Mol Biol 38:489-496.
32. 32. Takeda Y, Miyamori I, Yoneda T, Iki K, Hatakeyama H, Blair IA, Hsieh FY, Takeda R (1994). Synthesis of corticosterone in the vascular wall. Endocrinology 135:2283-2286.
33. 33. Souness GW, Morris DJ (1996). 11α- and 11β-Hydroxyprogesterone, potent inhibitors of 11β-hydroxysteroid dehydrogenase, possess hypotensinogenic activity in the rat. Hypertension 27:421-425.
34. 34. Gomez-Sanchez EP, Cox D, Foecking M, Ganjam V, Gomez-Sanchez CE (1996). 11β-Hydroxysteroid dehydrogenase of the choriocarcinoma cell line JEG-3 and their inhibition by glycyrrhetinic acid and other natural substances. Steroids 61:110-115.